Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITE1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02725762
Recruitment Status : Completed
First Posted : April 1, 2016
Last Update Posted : February 18, 2021
National Eye Institute (NEI)
Information provided by (Responsible Party):
LumiThera, Inc.

Brief Summary:
The purpose of this research study is to determine if photobiomodulation is an effective treatment of Dry Age-Related Macular Degeneration (AMD) and vision loss associated with the disease.

Condition or disease Intervention/treatment Phase
Age Related Macular Degeneration Device: LT-300 Active (PBM) Device: LT-300 Inactive (Sham) Not Applicable

Detailed Description:

The LumiThera LT 300® Light Delivery System is a stationary desktop instrument used to emit energy in the visible and near infrared spectrum. The LT-300® is designed for the ophthalmologist to use in the treatment of the eye with photobiomodulation (PBM), a process by which cellular mechanisms are induced by light. PBM is being utilized in many indications, such as wound healing, soft tissue injuries, joint pain, myofascial pain, nerve injuries, muscle fatigue for temporary improvement in blood flow and reduction in inflammation. The mechanism of PBM at the cellular level has been ascribed to the activation of mitochondrial respiratory chain components resulting in stabilization of metabolic function and initiation of a signaling cascade, which promotes cellular proliferation and cytoprotection. The LT-300® will provide a preset treatment of PBM to the subject's eye and retinal tissue through the open and closed eyelid.

Approximately 30 subjects meeting the eligibility requirements of the study will be randomly assigned in a 1:1 ratio to receive standard of care treatment for Dry AMD plus PBM treatment with the LT-300 system, or standard of care treatment for Dry AMD plus Sham treatment with the LT-300 system. Subjects randomized to each group will receive two 3-week treatment sessions (9 treatments per session) and follow-up visits extending to one year. The primary objective of the study is to evaluate the safety and efficacy of PBM with respect to visual and anatomical outcomes of subjects with Dry AMD.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-Masked, Randomized, Sham-Controlled, Parallel Group, Single-Center Study to Assess the Safety and Efficacy of Photobiomodulation in Subjects With Dry Age-Related Macular Degeneration
Study Start Date : March 2016
Actual Primary Completion Date : July 2018
Actual Study Completion Date : July 2018

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Photobiomodulation Treatment
Treatment with Photobiomodulation to the retina at specific wavelengths to the eye three times a week for three weeks, repeated at six months.
Device: LT-300 Active (PBM)
Sham Comparator: Sham Treatment
Sham treatment to the retina at specific wavelengths to the eye three times a week for three weeks, repeated at six months.
Device: LT-300 Inactive (Sham)

Primary Outcome Measures :
  1. Visual Acuity changes from baseline to month 12. [ Time Frame: Through study completion, an average of one year. ]
    Visual acuity will be measured using ETDRS VA letter scoring to test the difference between the sham and treatment subjects in mean change from Baseline to Month 12

Secondary Outcome Measures :
  1. Contrast Sensitivity [ Time Frame: Through study completion, an average of one year. ]
    Contrast Sensitivity will be measured using the FACT Contrast Sensitivity Chart to test the difference between the sham and treatment subjects in mean change from Baseline to Month 12

  2. Optical Coherence Tomography (OCT) [ Time Frame: Through study completion, an average of one year. ]
    OCT will be measured using the Spectralis SD-OCT to compare changes in dry AMD pathology.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients of both gender
  • Patients must have dry macular degeneration in the study eye
  • Best corrected visual acuity between 20/40 and 20/200
  • Patients must be competent to sign and have signed a consent form before study entry

Exclusion Criteria:

  • Visually significant cataracts.
  • Presence of a visually significant posterior capsule if prior cataract surgery has been performed.
  • Any visually significant disease process in any ocular structure that would affect vision unrelated to macular degeneration.
  • A patient can be enrolled if only one of their eyes meets the criteria. The other eye may be treated but not included in the study; for example advanced geographic atrophy.
  • Patients with severe clinically significant disease or unstable medical disorders including cardiovascular, hepatic, renal, neurological, endocrine, gastrointestinal, CNS or life threatening disease or current malignancy at the discretion of the investigators
  • Patients who are non-ambulatory or bed ridden
  • Female patients who are pregnant or of childbearing potential as effects of PBM on the developing human fetus are unknown.
  • Patients with a history of Epilepsy
  • Patients with a history of alcohol, drug or substance abuse in the past 6 months
  • Patients deemed uncooperative or non compliant with the requirements of the protocol.
  • Patients who have received any investigational drug or treatment within 30 days prior to study entry.
  • Patients who are not competent to understand and sign consent form.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02725762

Layout table for location information
Canada, Ontario
1929 Bayview Avenue, Unit 117
Toronto, Ontario, Canada, M4G 3E8
Sponsors and Collaborators
LumiThera, Inc.
National Eye Institute (NEI)
Layout table for investigator information
Principal Investigator: Samuel Markowitz, MD Private Practice
Principal Investigator: Robert G Devenyi, MD Ophthalmologist in Chief and Director of Retinal Services, The Donald K. Johnson Eye Center, University Health Network; Professor of Ophthalmology, The University of Toronto; Vitreoretinal Surgery Lead, The Kensington Eye Institute
Additional Information:
Layout table for additonal information
Responsible Party: LumiThera, Inc. Identifier: NCT02725762    
Other Study ID Numbers: CSP001
1R43EY025508-01 ( U.S. NIH Grant/Contract )
First Posted: April 1, 2016    Key Record Dates
Last Update Posted: February 18, 2021
Last Verified: February 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Keywords provided by LumiThera, Inc.:
Vision Loss
Additional relevant MeSH terms:
Layout table for MeSH terms
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases